Annals of internal medicine
-
Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting up to 5% of the population. VTE commonly manifests as lower-extremity deep venous thrombosis (DVT) or pulmonary embolism. ⋯ Many patients with VTE will have a chronic disease requiring long-term anticoagulation. Postthrombotic syndrome affects 25% to 40% of patients with DVT and significantly impacts function and quality of life.
-
Comment Meta Analysis
In type 2 diabetes, SGLT2 inhibitors reduced risk for serious hyperkalemia without increasing hypokalemia.
Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022;145:1460-70. 35394821.
-
Comment Randomized Controlled Trial
In IgA nephropathy, oral methylprednisolone reduced adverse kidney outcomes but increased adverse events.
Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327:1888-98. 35579642.
-
Comment Randomized Controlled Trial
In COVID-19 acute hypoxemia, awake prone positioning vs. usual care did not reduce intubation at 30 d.
Alhazzani W, Parhar KK, Weatherald J, et al. Effect of awake prone positioning on endotracheal intubation in patients with COVID-19 and acute respiratory failure: a randomized clinical trial. JAMA. 2022;327:2104-13. 35569448.
-
Multicenter Study Clinical Trial
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. ⋯ Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.